ライフサイエンスコーパス: activin receptor-like kinase

1 It includes the activin receptor like kinase 1 gene (ACVRLK1 or ALK1), a

2 d crossveinless 2 (CV2), both induced by the activin receptor like-kinase 1 (ALK1) when stimulated by

3 2 is caused by loss of function mutations in activin receptor-like kinase 1 (ACVRL1 or ALK1).

4 re linked to HHT: endoglin (ENG) in HHT1 and activin receptor-like kinase 1 (ACVRL1; ALK1) in HHT2.

5 Activin receptor-like kinase 1 (Acvrl1; Alk1) is a type

6 We show that vbg encodes activin receptor-like kinase 1 (Acvrl1; also known as Al

7 Activin receptor-like kinase 1 (ALK-1) has homology to t

8 Activin receptor-like kinase 1 (ALK-1), an orphan recept

9 ns were used to determine the involvement of activin receptor-like kinase 1 (ALK1) and ALK5 downstrea

10 dent on the endoglin signaling pathway using activin receptor-like kinase 1 (ALK1) Fc blocking peptid

11 Signaling through high-affinity activin receptor-like kinase 1 (ALK1) in endothelial cel

12 The activin receptor-like kinase 1 (ALK1) is a transforming

13 The activin receptor-like kinase 1 (ALK1) is a type I recept

14 Activin receptor-like kinase 1 (ALK1) is an endothelial

15 Activin receptor-like kinase 1 (ALK1) is an endothelial-

16 e insight into this question by studying the activin receptor-like kinase 1 (ALK1) pathway.

17 Genetic and molecular studies suggest that activin receptor-like kinase 1 (ALK1) plays an important

18 Genetic and molecular studies suggest that activin receptor-like kinase 1 (ALK1), a transforming gr

19 FK506 released FKBP12 from type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3 an

20 Activin receptor-like kinase 1 (ALK1), an endothelial ce

21 -of-function mutations in the genes encoding activin receptor-like kinase 1 (ALK1), endoglin, Smad4,

22 pro-domain-complexed BMP9 to type I receptor activin receptor-like kinase 1 (ALK1), type II receptors

23 In zebrafish embryos, arterial expression of activin receptor-like kinase 1 (alk1), which encodes a T

24 g was reduced in TbetaRII(+/-) ECs; however, activin receptor-like kinase 1 (ALK1)-mediated Smad1/5 p

25 mutations in one of several genes, including activin receptor-like kinase 1 (ALK1).

26 emorrhagic telangiectasia type 2 (HHT2) with activin receptor-like kinase 1 (ALK1; ACVRL1) mutations

27 e arterial-specific TGFbeta type I receptor, activin receptor-like kinase 1 (ALK1; ACVRL1), causes he

28 Subsequent activation of activin receptor-like kinase 1 enhances expression of No

29 The activin receptor-like kinase 1 gene (ALK-1) is the secon

30 Small interfering RNA knockdown of activin receptor-like kinase 1 inhibited the BMP9-induce

31 to the lack of MGP induces expression of the activin receptor-like kinase 1, a BMP type I receptor, i

32 bone morphogenetic protein receptor type 2, activin receptor-like kinase 1, endoglin, and mothers ag

33 ovenous fate, acting via EphrinB2 and ACVRL1/activin receptor-like kinase 1.

34 ta-receptor proteins, including endoglin and activin-receptor-like kinase 1 (ALK1), and BMPR2.

35 pulmonary vascular endothelial expression of activin-receptor-like kinase 1 in normal and diseased pu

36 We identified amino acid changes in activin-receptor-like kinase 1 that were inherited in su

37 s-of-function mutations in the gene encoding activin receptor-like kinase-1 (ACVRL1).

38 Activin receptor-like kinase-1 (ALK1) is an endothelial

39 endogenous BMP-2 ligand and ALK-1 receptor (activin receptor-like kinase-1; known to activate Smads

40 IL-1beta reduced the number of activin receptor-like kinase 2 (ALK-2) and ALK-3 recepto

41 dependent upon the type I TGFbeta receptor, activin receptor-like kinase 2 (ALK2), and the downstrea

42 xpression of type I TGFbeta receptors, chick activin receptor-like kinase 2 and 5 increased with a 2.

43 Constitutively active activin receptor-like kinase 2 inhibited Galpha(i2) prom

44 increased with a 2.3-fold higher increase in activin receptor-like kinase 2.

45 f the pVent reporter, which is downstream of activin receptor-like kinase 2.

46 c ossification in transgenic mice expressing activin receptor-like kinase-2 (ALK2) Q207D, a constitut

47 pe II receptor and the type I receptor Alk2 (activin receptor-like kinase-2) decreased.

48 hogenetic protein signaling, most likely via activin receptor-like kinase 3.

49 sociate with either nodal or the type I ALK (activin receptor-like kinase) 4 receptor in coimmunoprec

50 Activin receptor-like kinase 5 (ALK5) is the major type

51 to the TGF-beta type I receptor (also termed activin receptor-like kinase 5 (ALK5)), in a similar fas

52 growth factor beta receptor I (TGF-betaRI) (activin receptor-like kinase 5 [ALK-5]) and TGF-beta rec

53 he p3TP-lux reporter, which is downstream of activin receptor-like kinase 5 and had no effect on the

54 hese data are consistent with a role for the activin receptor-like kinase 5 in the progression of idi

55 potential of a well-characterized and potent activin receptor-like kinase 5 inhibitor, SB525334 [6-(2

56 at, conversely, the type I TGF-beta receptor activin receptor-like kinase 5 is dispensable for trypsi

57 Aberrant signaling via TGF-beta receptor I/activin receptor-like kinase 5 may be important for both

58 min preferentially induces activation of the activin receptor-like kinase 5 pathway of TGF-beta recep

59 pid acting, and mediated by TGF-beta-induced activin receptor-like kinase 5 signaling in endothelial

60 hic PAH and imply that strategies to inhibit activin receptor-like kinase 5 signaling may have therap

61 oter activity, whereas constitutively active activin receptor-like kinase 5 stimulated Galpha(i2) pro

62 n a small increase in TGF-beta signaling via activin receptor-like kinase 5 to maintain early integri

63 TGFbetaRI kinase/activin receptor-like kinase 5 was inhibited with pharma

64 ylated via JAK1 and acts as a critical ALK5 (activin receptor-like kinase 5) downstream signaling mol

65 ed the TGF-beta type 1 receptor (also termed activin receptor-like kinase 5) in renal epithelial cell

66 ve inhibitor of the type 1 TGF-beta receptor activin receptor-like kinase 5, orally active) to inhibi

67 or-beta superfamily receptors and found that activin receptor-like kinase-6 extracellular domain most

68 nt lost-a-fin (laf) is defective in the gene activin receptor-like kinase 8 (alk8), which encodes a n

69 etween pro- and anti-angiogenic signaling by activin receptor-like kinase (ALK) 1, 5, and TGF-beta ty

70 Several type I receptors exist although activin receptor-like kinase (ALK) 5 mediates the majori

71 I receptor serine/threonine kinase known as activin receptor-like kinase (ALK) 5.

72 , which was impeded by ALK5 knockdown and by activin receptor-like kinase (ALK) receptor inhibitor SB

73 those induced by the receptor serine kinase, activin receptor-like kinase (ALK)-2.

74 BMP-binding TGF-beta superfamily receptors, activin receptor-like kinase (ALK)3/6, and the Smad2/3 p

75 1542) that was identified as an inhibitor of activin receptor-like kinase (ALK)5 (the TGF-beta type I

76 nase domain of the TGF-beta type I receptor [activin receptor-like kinase (ALK)5] and the substrate,

77 Activin receptor-like kinase (ALK)7 is a type I serine/t

78 ized the chicken homologues of two mammalian activin receptor-like kinases (ALK), ALK2 and ALK5, and

79 As type I activin receptor-like kinases (ALKs) are necessary for S

80 K), transforming growth factor beta receptor/activin receptor-like kinase beta, estrogen receptor, an

81 in zebrafish embryos harboring a mutation in activin receptor-like kinase I (alk1), which encodes a T

82 treatment with Fstl3 or by a pharmacological activin receptor-like kinase inhibitor.

83 treatment of SB-431542, an inhibitor of the activin receptor-like kinase receptors, to enhance myoge

84 anti-activin A-blocking Ab or inhibitors of activin receptor-like kinase receptors.